Fentanyl is under clinical development by iX Biopharma and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Fentanyl’s likelihood of approval (LoA) and phase transition for Cancer Pain took place on 17 Feb 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Fentanyl Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Fentanyl (Wafernyl) is under development for the treatment of breakthrough cancer pain. The therapeutic candidate is formulated as a wafer and is administered through sublingual route. The drug candidate acts by targeting mu opioid receptor. It is developed based on WaferiX drug delivery technology.
It was also under development for the treatment of acute pain, post-operative pain and traumatic pain.
iX Biopharma overview
iX Biopharma is a pharmaceutical and nutraceutical company. It discover, develops and commercializes novel therapies to treat diseases targeting central nervous system. The company’s products include Wafesil, a sublingual oral wafer containing sildenafil citrate and Silcap, an oral ingestion containing sildenafil citrate for the treatment of male erectile dysfunction. iX Biopharma provides pipeline products such as Wafermine, a sublingual ketamine oral wafer used to manage moderate to severe pain and pioid analgesia, Xativa, a sublingual wafer containing cannabidiol (CBD) against anxiety, movement disorder and chronic inflammation condition. BnoX, a sublingual buprenorphine oral wafer for pain management and Wafernyl, a sublingual fentanyl oral wafer used in breakthrough of cancer pain. iX Biopharma utilizes its proprietary formulation Waferix Sublingual to develop its products. The company conducts its research and development activities in Singapore and Australia. iX Biopharma is headquartered in Singapore.
Quick View Fentanyl LOA Data
|Highest Development Stage|